Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Phenotypic characterization of FSHD-like FLExDUX4 minipigs
Investigator: Peter L. Jones, PhD, University of Nevada, Reno School of Medicine All forms of FSHD are caused by misexpression of DUX4 (double homeobox protein 4) in skeletal muscles; thus, the…Read More
Matrix Bound Nanovesicles (MBV) as a Therapy for FSHD
Investigator: Dr. George Hussey, University of Pittsburgh Regenerative Medicine provides an alternative FSHD treatment strategy for promoting new tissue growth using Extracellular Matrix (ECM) bioscaffolds. ECM bioscaffolds serve as a biochemical…Read More
Working Towards an ASO Treatment for FSHD2 Patients
Investigator: Dr. Stanley Crooke FSHD is a rare disease. FSHD2 is even more rare. Only 5% of all FSHD patients have FSHD2. We don’t want them to get left behind. The…Read More